Previous close | 32.85 |
Open | 32.44 |
Bid | 31.74 x 900 |
Ask | 31.76 x 900 |
Day's range | 31.40 - 32.94 |
52-week range | 27.38 - 174.32 |
Volume | |
Avg. volume | 8,113,148 |
Market cap | 5.108B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | N/A |
EPS (TTM) | -43.41 |
Earnings date | 25 Jul 2022 - 29 Jul 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 64.84 |
Would Teladoc (NYSE: TDOC) make a good fit for Berkshire (NYSE: BRK.A) (NYSE: BRK.B)? In this clip from "The Rank" on Motley Fool Live, recorded on April 25, Motley Fool contributor Zane Fracek makes the case for why he'd like to see Berkshire expand into healthcare and telemedicine given the growth opportunity ahead.
Investors can look at the current market decline in one of two ways. Investors with long-term mindsets can find plenty of attractive opportunities in today's market. Viatris (NASDAQ: VTRS) appears to be a textbook value stock.
A surging stock market helped push shares of Teladoc Health (NYSE: TDOC) higher by more than 9% on Friday. The raiser was Piper Sandler prognosticator Jessica Tassan, who now thinks the shares are worth $42, a bump from her previous estimation of $41. According to analyst-recommendation tracking website TheFly.com, Tassan made the adjustment on the basis of conversations with Teladoc officials and an analysis of the direct-to-consumer healthcare market, among other factors.